Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice.

Pers YM, Fortunet C, Constant E, Lambert J, Godfrin-Valnet M, De Jong A, Mercier G, Pallot Prades B, Wendling D, Gaudin P, Jorgensen C, Marotte H, Maillefert JF.

Rheumatology (Oxford). 2014 Jan;53(1):76-84. doi: 10.1093/rheumatology/ket301. Epub 2013 Sep 19.

2.

[Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].

Avdeeva AS, Aleksandrova EN, Novikov AA, Cherkasova MV, Panasyuk EY, Nasonov EL.

Ter Arkh. 2013;85(5):24-9. Russian.

PMID:
23819335
3.

Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria.

Iking-Konert C, Aringer M, Wollenhaupt J, Mosch T, Tuerk S, Feist E, Burmester GR.

Ann Rheum Dis. 2011 Nov;70(11):1986-90. doi: 10.1136/ard.2011.152678. Epub 2011 Aug 29.

4.

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).

Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A.

Ann Rheum Dis. 2011 May;70(5):755-9. doi: 10.1136/ard.2010.139725. Epub 2010 Dec 27.

5.

Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.

Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P.

Rheumatology (Oxford). 2008 Apr;47(4):495-9. doi: 10.1093/rheumatology/ken002. Epub 2008 Mar 3.

6.

Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.

Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Nagamine R, Nakashima H, Otsuka T, Saikawa I, Shono E, Suematsu E, Tsuru T, Wada K, Iwamoto Y.

Mod Rheumatol. 2010 Aug;20(4):343-52. doi: 10.1007/s10165-010-0290-x. Epub 2010 May 18.

PMID:
20480201
7.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

8.

Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.

Backhaus M, Kaufmann J, Richter C, Wassenberg S, Roske AE, Hellmann P, Gaubitz M.

Clin Rheumatol. 2015 Apr;34(4):673-81. doi: 10.1007/s10067-015-2879-0. Epub 2015 Jan 29.

9.

Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.

Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M, Miyake H, Takagi H, Kato T, Terabe K, Wanatabe T, Tsuchiya H, Kida D, Shioura T, Funahashi K, Kato D, Matsubara H, Takahashi N, Hattori Y, Asai N, Ishiguro N.

Mod Rheumatol. 2013 Sep;23(5):977-85. doi: 10.1007/s10165-012-0782-y. Epub 2012 Oct 26.

PMID:
23099471
10.

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.

Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, Lorenzen T, Hansen A, Hansen MS, Jacobsen MS, Dreyer L, Hetland ML; all departments of rheumatology in Denmark.

Ann Rheum Dis. 2011 Jul;70(7):1216-22. doi: 10.1136/ard.2010.140129. Epub 2011 May 8.

PMID:
21551512
11.

Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis.

Pers YM, Schaub R, Constant E, Lambert J, Godfrin-Valnet M, Fortunet C, Bourichi W, Prades BP, Wendling D, Gaudin P, Jorgensen C, Maillefert JF, Marotte H.

Joint Bone Spine. 2015 Jan;82(1):25-30. doi: 10.1016/j.jbspin.2014.07.010. Epub 2014 Sep 17.

PMID:
25241333
12.

Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.

Suzuki T, Horikoshi M, Sugihara M, Hirota T, Ogishima H, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Chino Y, Matsumoto I, Sumida T.

Mod Rheumatol. 2013 Jul;23(4):782-7. doi: 10.1007/s10165-012-0746-2. Epub 2012 Sep 14.

PMID:
22975733
13.

Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.

Kojima T, Yabe Y, Kaneko A, Takahashi N, Funahashi K, Kato D, Hanabayashi M, Asai S, Hirabara S, Asai N, Hirano Y, Hayashi M, Miyake H, Kojima M, Ishiguro N.

Rheumatology (Oxford). 2015 Jan;54(1):113-20. doi: 10.1093/rheumatology/keu302. Epub 2014 Aug 7.

14.

Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice.

Bykerk VP, Ostör AJ, Alvaro-Gracia J, Pavelka K, Ivorra JA, Graninger W, Bensen W, Nurmohamed MT, Krause A, Bernasconi C, Stancati A, Sibilia J.

Ann Rheum Dis. 2012 Dec;71(12):1950-4. doi: 10.1136/annrheumdis-2011-201087. Epub 2012 May 21.

15.

High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.

Daïen CI, Gailhac S, Audo R, Mura T, Hahne M, Combe B, Morel J.

Rheumatology (Oxford). 2015 Apr;54(4):601-8. doi: 10.1093/rheumatology/keu363. Epub 2014 Sep 16.

16.

Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.

Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gómez-Reino J, Sebba A, Pilson R, Williams S, Van Vollenhoven R.

J Rheumatol. 2013 Jun;40(6):768-80. doi: 10.3899/jrheum.120687. Epub 2013 Mar 1.

PMID:
23457383
17.

Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register.

Forsblad-d'Elia H, Bengtsson K, Kristensen LE, Jacobsson LT.

Rheumatology (Oxford). 2015 Jul;54(7):1186-93. doi: 10.1093/rheumatology/keu455. Epub 2014 Dec 13.

18.

Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.

Nakashima Y, Kondo M, Fukuda T, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Maekawa M, Nishizaka H, Nagamine R, Nakashima H, Otsuka T, Shono E, Suematsu E, Shimauchi T, Tsuru T, Wada K, Yoshizawa S, Yoshizawa S, Iwamoto Y.

Mod Rheumatol. 2014 Mar;24(2):258-64. doi: 10.3109/14397595.2013.854069.

PMID:
24593201
19.

Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting.

Vázquez I, Graell E, Gratacós J, Cañete JD, Viñas O, Ercilla MG, Gómez A, Hernández MV, Rodríguez-Cros JR, Larrosa M, Sanmartí R.

Clin Exp Rheumatol. 2007 Mar-Apr;25(2):231-8.

PMID:
17543147
20.

Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.

Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ML, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, Cerinic MM, Montecucco C, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF; GISEA group.

J Rheumatol. 2007 Aug;34(8):1670-3. Epub 2007 Jul 1. Erratum in: J Rheumatol. 2007 Sep;34(9):1947.

PMID:
17611987
Items per page

Supplemental Content

Write to the Help Desk